Table of Contents
- Key safety points
- Overview
- Forms and Delivery
- Evidence for Health Benefits
- Recommended Dosing
- Safety and Side Effects
- Drug Interactions
- Dietary Sources
- References
Key safety points
- People who are critically ill, immunocompromised, tube-fed or have a central venous catheter have developed bloodstream infections (bacteremia or fungemia) from probiotic organisms, some of them fatal [120, 122, 124]. If you are in one of these groups, check with your doctor first; with fever and shivering, confusion or a racing heart, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.
- The FDA warned in 2023 that probiotics given to preterm infants may cause infection or invasive, potentially fatal disease, and in 2014 a preterm infant died of a mold infection linked to a contaminated probiotic powder. Use them in preterm infants only under medical supervision [138, 139].
- In a trial of patients having major abdominal operations, perioperative VSL#3 raised 30-day readmissions (16.4% vs 4.4%), often for dehydration from diet intolerance or diarrhea [130].
- Anaphylaxis from inulin, a prebiotic found in some vegetables and processed foods, has been reported; with trouble breathing or swelling of the face or throat, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) [133].
- In healthy people, side effects are usually minor, and short-term use in trials did not raise the overall rate of adverse events [121, 138].
1. Overview
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host [1]. This definition, established by the International Scientific Association for Probiotics and Prebiotics (ISAPP), distinguishes probiotics from the many "live culture" products that have not demonstrated health benefits in controlled trials. Most probiotic organisms are bacteria — primarily from the genera Lactobacillus (now reclassified into several genera within the family Lactobacillaceae), Bifidobacterium, Streptococcus, Enterococcus, Escherichia, and Bacillus — though the yeast Saccharomyces boulardii is also widely used [1, 2].
Probiotics should not be confused with prebiotics, which are typically complex carbohydrates (such as inulin and fructo-oligosaccharides) that serve as metabolic fuel for beneficial gut microorganisms [3]. Products containing both prebiotics and probiotics are called synbiotics. Nor should probiotics be confused with postbiotics — preparations of dead or fragmented microorganisms, with or without their metabolites, that confer a health benefit [4].
The Gut Microbiome
The human gastrointestinal tract is colonized by trillions of microorganisms — bacteria, archaea, viruses, fungi, and protozoa — collectively known as the gut microbiota or microbiome [2]. The composition and activity of this microbial community profoundly influences human health, affecting digestion, nutrient absorption, immune function, metabolic regulation, and even neurological signaling via the gut-brain axis.
Probiotics are consumed orally and exert their effects primarily in the gastrointestinal tract, where they may transiently colonize the gut mucosa in highly individualized patterns depending on the baseline microbiota, the probiotic strain used, and the region of the GI tract [5]. This means the same probiotic may work differently in different individuals — a critical point that helps explain the variability seen in clinical trials.
Mechanisms of Action
Probiotics exert health benefits through multiple mechanisms, some shared broadly across species and others unique to specific strains [1, 2]:
- Nonspecific mechanisms (shared across many strains): Inhibition of pathogenic microorganism growth via colonization resistance and antimicrobial substance production; improvement of intestinal transit; production of short-chain fatty acids (SCFAs); reduction of luminal pH in the colon
- Species-specific mechanisms: Vitamin synthesis, gut barrier reinforcement, bile salt metabolism, enzymatic activity, and toxin neutralization
- Strain-specific mechanisms: Cytokine production, specific immunomodulatory activities, and effects on the endocrine and nervous systems
Because effects can be strain-specific, recommendations for probiotic use need to be strain-specific — and researchers should account for strain differences when designing studies and pooling data [2, 6, 7].
Strain Nomenclature
Probiotics are identified by their genus, species, subspecies (if applicable), and an alphanumeric strain designation [2]. For example:
| Genus | Species | Subspecies | Strain | Common Name |
|---|---|---|---|---|
| Lacticaseibacillus (formerly Lactobacillus) | rhamnosus | — | GG | LGG |
| Bifidobacterium | animalis | lactis | DN-173 010 | Bifidus regularis |
| Bifidobacterium | longum | longum | 35624 | Bifantis |
| Saccharomyces | boulardii | — | CNCM I-745 | — |
In 2020, the Lactobacillus genus was restructured into 23 novel genera, though many products and studies still use the older nomenclature [8]. This article uses the genus names that were in use at the time each study was conducted.
Why Strain Specificity Matters
A key principle in probiotic science is that benefits demonstrated for one strain cannot be assumed to apply to another strain of the same species. Lactobacillus rhamnosus GG has different clinical effects than Lactobacillus rhamnosus R0011, even though both belong to the same species. A review of 65 randomized trials compared single strains with mixtures that contained the same strain and found that, in most cases, the mixture worked no better [9]. There were exceptions: L. rhamnosus GG plus B. lactis Bb12 cleared H. pylori more often than L. rhamnosus GG on its own; in contrast, L. rhamnosus GG on its own protected against necrotizing enterocolitis better than two mixtures that held other B. lactis strains [9].
2. Forms and Delivery
Supplement Forms
Probiotic supplements are available as capsules, tablets, powders, liquids, chewables, gummies, and sachets. They may contain a single strain or multiple strains. The number of viable cells is measured in colony-forming units (CFU). Many products contain 1 to 10 billion CFU per dose, though some contain 50 billion CFU or more [2, 10].
Higher CFU counts are not necessarily more effective. The best dose depends on the strain and the product [138].
Label Reading
Under current FDA rules, the Supplement Facts label only has to give the total weight of the microorganisms, which counts live and dead cells alike and says nothing about how many are viable [13, 138]. Counts fall as a product ages, so a CFU figure guaranteed to the expiry date is more useful than one given for the date the product was made [138].
The International Scientific Association for Probiotics and Prebiotics (ISAPP) advises manufacturers to list total CFU — ideally for each strain — through the expiration date [15]. Products that state amounts only "at time of manufacture" should be viewed with caution, though FDA regulations require that stated amounts still be present at time of use if the product is consumed before its expiration date [14].
Survival Through the GI Tract
For a probiotic to exert its effects, the organisms generally must survive passage through stomach acid and reach the intestines alive. Survival depends on the species and formulation:
- Food helps bacterial probiotics. In a lab model of the upper gut, a multi-strain probiotic survived best when given with a meal or 30 minutes before it, and the fat in the meal seemed to matter more than its protein [18].
- Yeast probiotics (Saccharomyces boulardii) survived the same model whatever the meal timing or the buffering of the food [18].
Storage Requirements
The WGO advises checking the label for storage conditions: some products need refrigeration, while others keep at room temperature [138].
Fermented Food Sources
Some fermented foods are natural sources of beneficial microorganisms, though not all fermented foods contain proven probiotic strains [20]:
- Yogurt is made using Lactobacillus bulgaricus and Streptococcus thermophilus as starter cultures. Some yogurts also contain added probiotic strains from Bifidobacterium or Lactobacillaceae [20, 138].
- Kefir is a fermented milk drink containing diverse communities of bacteria and yeast.
- Fermented foods with live cultures but without proven probiotic strains include many cheeses, kimchi, kombucha, sauerkraut, miso, pickles, and raw unfiltered apple cider vinegar [21].
- Some fermented foods lose their live cultures during processing — for example, sourdough bread and most commercially pickled vegetables are heated after fermentation and contain no live organisms when consumed.
Kombucha: Special Considerations
Kombucha is a fermented tea that contains live cultures but does not usually contain proven probiotic organisms [138]. Points to know:
- A 54-year-old woman developed severe lactic acidosis linked to drinking kombucha, and she recovered once she stopped the tea [23].
- In a laboratory study, commercial kombuchas were acidic (pH 2.82-3.66) and dissolved more calcium from tooth mineral than cola drinks did, which suggests they can erode enamel [24].
- If you are pregnant or breastfeeding, or have a weakened immune system, ask your doctor before drinking kombucha.
How Long Do Probiotics Persist?
Probiotics seem to change the gut lining only briefly, and the effect differs from person to person [5]. For a specific condition, follow the duration used in trials of that strain.
3. Evidence for Health Benefits
Irritable Bowel Syndrome (IBS)
IBS is a common functional gastrointestinal disorder characterized by recurrent abdominal pain, bloating, and altered bowel habits. Growing evidence implicates the gut microbiota in IBS pathophysiology — proinflammatory species such as Enterobacteriaceae are overrepresented in IBS patients, who typically also have reduced populations of Lactobacillus and Bifidobacterium [27, 28].
Overall efficacy: A meta-analysis of 23 RCTs in 2,575 patients found that probiotics reduced the risk of persistent IBS symptoms by 21% [29]. Various species showed beneficial effects on global symptoms, abdominal pain, bloating, and flatulence, though study quality was generally low. A second meta-analysis of 15 RCTs (n=1,793) found that probiotics reduced overall symptom severity and abdominal pain more than placebo after 8-10 weeks; in children, probiotics also improved mucosal barrier function [30].
Multi-strain vs single-strain: A systematic review of 35 RCTs evaluating 16 single-strain and 19 multi-strain products in 3,406 adults with IBS found that multi-strain products were more likely to produce clinically meaningful improvements. Of the studies finding significant global symptom reduction (14 of 29 trials) or clinically meaningful pain reduction (8 of 34 trials), most used multi-strain products. Only trials of multi-strain products found clinically meaningful improvement in quality of life [31, 32].
Strain-specific effects: In a meta-analysis of 10 RCTs (n=877 adults), probiotics containing Bifidobacterium breve, B. longum, or Lactobacillus acidophilus species significantly lowered pain scores compared to placebo [33]. In contrast, Streptococcus thermophilus, B. animalis, B. infantis, L. casei, L. plantarum, L. bulgaricus, and S. boulardii had no significant effect on pain. Flatulence improved with all tested probiotics, and abdominal distension improved with B. breve, B. infantis, L. casei, or L. plantarum species [33].
Specific strains with clinical evidence for IBS:
- Bifidobacterium infantis 35624: In 362 women with IBS, a capsule of 1 x 10^8 CFU daily for 4 weeks eased abdominal pain, bloating and other symptoms more than placebo; doses of 1 x 10^6 and 1 x 10^10 CFU did no better than placebo [34].
- Symprove (a liquid multi-strain product): In 186 adults with IBS, 12 weeks at 1 mL/kg/day improved overall symptom severity scores more than placebo but did not improve quality of life [35].
- VSL#3 (450 billion bacteria a day): In 25 people whose IBS mainly caused diarrhea, 8 weeks eased bloating but not abdominal pain, gas, urgency or overall symptom relief [36].
- Bacillus coagulans MTCC 5856: In a trial of people whose IBS mainly caused diarrhea (18 on the probiotic, 18 on placebo), a 2 x 10^9 CFU tablet daily for 90 days, added to standard care, reduced bloating, vomiting, diarrhea, pain and stool frequency more than placebo [38].
- Lactobacillus rhamnosus GG: In 141 children with IBS or functional abdominal pain, 8 weeks of LGG reduced how often and how badly their abdomen hurt, mainly in those with IBS [39]. In 60 children with functional abdominal pain, Lactobacillus reuteri DSM 17938 at 200 million CFU daily for 4 weeks lowered pain intensity [40].
Antibiotic-Associated Diarrhea (AAD)
Antibiotics disrupt the intestinal microbiome, reducing microbial diversity, which can lead to osmotic diarrhea, loss of colonization resistance, and increased intestinal motility [41]. Up to 30% of patients on antibiotics develop AAD [42]. Inpatients, children under 2, and adults over 65 are at highest risk [41, 42].
Overall risk reduction: Meta-analyses indicate that specific probiotic strains may reduce the risk of AAD by approximately 51% [138]. However, benefits depend on the type of antibiotic, the probiotic strain, patient age, and care setting. Probiotics have been associated with reduced AAD risk in adults aged 18 to 64 years but not in adults over 65 years [44].
LGG for AAD: A systematic review and meta-analysis of 12 RCTs (n=1,499 children and adults) found that LGG reduced AAD risk from 22.4% to 12.3% [45]. When children and adults were analyzed separately, the difference was statistically significant only in children [45]. The trials gave 4 x 10^8 to 12 x 10^10 CFU for 10 days to 3 months, and 1 to 2 x 10^10 CFU/day reduced AAD risk in children by 71% [138]. Starting probiotics within 2 days of the first antibiotic dose is more effective than starting later [138].
Saccharomyces boulardii for AAD: A systematic review and meta-analysis of 21 RCTs (n=4,780 adults and children aged 6 months to 65 years) found that S. boulardii reduced AAD risk in adults from 17.4% to 8.2% and in children from 20.9% to 8.8% compared to placebo [46]. Various doses were tested with no clear dose-dependent effect.
Other effective combinations for AAD:
- L. acidophilus CL1285 and L. casei LBC80R: 50-100 billion CFU reduced AAD incidence [47].
- HOWARU Restore (a four-strain combination): In 503 adult inpatients on antibiotics, AAD incidences were 12.5, 19.6, and 24.6% with 17 billion CFU daily, a lower dose and placebo [48].
- S. boulardii CNCM I-745: In healthy volunteers taking amoxicillin-clavulanate, adding it lessened the shift in gut bacteria and lowered diarrhea scores [49].
- L. rhamnosus R0011 plus L. helveticus R0052: In healthy adults taking amoxicillin-clavulanate, it did not change stool consistency or frequency, though a post hoc analysis found that diarrhea-like episodes ended 1 full day sooner [50].
Guideline positions: ESPGHAN (2023) recommends administering LGG or S. boulardii at 5 x 10^9 CFU/day or more starting simultaneously with antibiotics to prevent AAD in children with risk factors [51]. There is no evidence that using more than one probiotic strain provides additional benefit over effective single strains [2, 45].
Timing and antibiotic interaction: Starting a probiotic within 2 days of the first antibiotic dose appears to work better than starting later [138]. One study found that a multi-strain probiotic given after a course of antibiotics slowed the return of the person's own gut bacteria [52].
Atopic Dermatitis (Eczema)
Atopic dermatitis is the most common form of eczema, affecting 15-20% of children and 1-3% of adults worldwide [53]. Probiotics have been evaluated for both prevention and treatment.
Prevention: A 2018 meta-analysis of 27 RCTs and one controlled cohort study (n=6,907 infants and children) found that probiotic treatment during pregnancy and infancy significantly reduced the risk of atopic dermatitis from 34.7% to 28.5% between ages 6 months and 9 years [54]. Key findings:
- Using probiotics during both prenatal and postnatal periods significantly reduced incidence; using them during only one period did not
- L. rhamnosus and L. paracasei significantly reduced incidence, whereas L. reuteri and L. acidophilus did not
In contrast, a meta-analysis of 5 RCTs (n=889) found that LGG supplementation specifically did not reduce eczema risk in children up to age 4 years, regardless of whether given directly to children or via maternal supplementation [55].
Treatment: A meta-analysis of 13 RCTs (n=1,070 participants age 18 or younger) found that 4-8 weeks of probiotic treatment significantly reduced SCORAD scores (a measure of eczema severity) [56]. However:
- Benefits were seen in children aged 1-18 years but not in infants younger than 1 year
- Lactobacillus, L. fermentum, and multi-strain mixtures reduced SCORAD values, while LGG and L. plantarum had no effect
Another meta-analysis of 8 RCTs (n=741 participants from birth to 36 months) found that Lactobacillus-containing probiotics reduced symptom severity in infants and toddlers, but Bifidobacterium-containing probiotics did not. Treatment significantly improved moderate-to-severe disease but not mild forms [57].
A Cochrane Review of 39 RCTs (n=2,599 participants aged 1-55 years) concluded that while probiotics might slightly reduce SCORAD scores, the differences were not clinically significant. The reviewers concluded that current evidence does not support the use of probiotics for eczema treatment [58].
Practical guidance for eczema prevention: In one trial, L. rhamnosus HN001 at 6 billion CFU daily, given to mothers from 35 weeks' gestation until 6 months after birth while breastfeeding and to their babies until age 2 years, lowered eczema rates through age 11 years [60].
Pediatric Acute Infectious Diarrhea
Acute diarrhea (loose stools with at least 3 episodes in 24 hours) is common in children and usually self-limiting [61]. A 2020 Cochrane Review of 82 RCTs (n=12,127, primarily children) found that probiotics reduced the risk of diarrhea lasting 48 hours or more by 36% and reduced mean diarrhea duration by 21.3 hours [62]. However, when only low-risk-of-bias studies were included, the benefit disappeared.
Specific strains:
- LGG: An assessment of 11 RCTs (n=2,444) showed LGG is most effective for infectious diarrhea at a daily dose of at least 10^10 CFU, reducing diarrhea duration by approximately 1 day [63, 64].
- Saccharomyces boulardii: A review of 22 trials (n=2,440 children aged 1 month to 15 years) found that S. boulardii (most commonly 10^9 to 10^10 CFU/day for 5-10 days) reduced diarrhea duration and stool frequency, also by approximately 1 day [65].
However, two large 2018 trials in children seen in emergency departments found that a 5-day course did no better than placebo: one gave LGG to 971 children in the United States, and the other gave L. rhamnosus R0011 plus L. helveticus R0052 to 886 children in Canada [66, 67]. This may reflect that most episodes in developed countries are self-limiting and require only rehydration therapy.
Guideline disagreement: ESPGHAN (2023) recommends LGG, S. boulardii, L. reuteri, or L. rhamnosus + L. reuteri combinations for pediatric acute gastroenteritis, though the grade of recommendation is weak and certainty of evidence low [51]. In contrast, the AGA (2020) recommended against probiotic use for acute infectious gastroenteritis in children in the United States and Canada, citing concerns about bias in positive studies (mostly conducted in India, Italy, Poland, Turkey, and Pakistan) [68].
Traveler's diarrhea: A placebo-controlled study of 3,000 Austrian travelers found that S. boulardii at 250 mg or 1,000 mg daily cut the rate of diarrhea, with a dose-dependent effect that was greatest in those who took it reliably [70]. A smaller study tested LGG for the same purpose in American travelers [69].
Inflammatory Bowel Disease (IBD)
IBD encompasses ulcerative colitis and Crohn's disease — chronic inflammatory conditions likely caused by a combination of genetic and environmental factors, including immune dysfunction [68]. Researchers have investigated whether probiotics can help manage IBD given the alterations in gut microbiome observed in these patients [68].
Ulcerative colitis: A 2020 AGA systematic review examined 17 trials using various probiotic formulations in 1,673 children and adults [68]. There is some evidence that probiotics may modestly reduce disease activity in mild-to-moderate ulcerative colitis when combined with conventional therapies. A 2020 Cochrane Review of 14 studies (n=865) indicated that probiotics may help induce remission and that combining probiotics with 5-ASA may be superior to 5-ASA alone, though evidence was limited and of low certainty [71]. A separate Cochrane Review of 12 studies (n=1,473) found the effects on maintaining remission uncertain due to small study sizes [72].
Crohn's disease: The same AGA review examined 12 trials in 689 children and adults and found no evidence that probiotics help induce or maintain remission in Crohn's disease [68].
Clinical guidelines: AGA recommends using probiotics in adults and children with ulcerative colitis or Crohn's disease only in the context of clinical trials [68]. The British Society of Gastroenterology (2019) concluded that while probiotics may be modestly beneficial for ulcerative colitis, they should not be routinely used, and found no evidence of benefit for Crohn's disease [73]. ESPGHAN (2023) stated insufficient evidence to recommend for or against probiotics in pediatric IBD [51].
Cholesterol and Cardiovascular Effects
Probiotics may reduce cholesterol through several mechanisms: increasing bile salt hydrolase activity (which increases bile acid synthesis and thus reduces serum cholesterol), binding cholesterol in the small intestine to reduce absorption, incorporating cholesterol into bacterial cell membranes, and producing short-chain fatty acids that modulate hepatic cholesterol metabolism [74, 75, 76].
Meta-analysis evidence: A meta-analysis of 30 RCTs (n=1,624, mostly adults) found that 3-12 weeks of probiotic use reduced total cholesterol by a mean of 7.8 mg/dL and LDL cholesterol by 7.3 mg/dL versus placebo [77]. Benefits were slightly greater in studies lasting 8 or more weeks and in participants with baseline total cholesterol above 240 mg/dL. Among strains included in more than three studies, L. acidophilus, a mixture of L. acidophilus and B. lactis, and L. plantarum were associated with significant reductions, while L. helveticus and E. faecium were not.
A smaller meta-analysis of 11 RCTs (n=602 adults) found 6.6 mg/dL lower total cholesterol and 8.5 mg/dL lower LDL cholesterol with probiotic use, with no significant effect on HDL [78]. Effects were most pronounced with treatment longer than 4 weeks, in those with hypercholesterolemia, and in those aged 45 or older.
A review focusing on multi-strain vs single-strain products found that multi-strain probiotics produced statistically significant reductions in total cholesterol (12.0 mg/dL) and LDL cholesterol (20.1 mg/dL), while single-strain products did not [79]. However, a review of 14 studies in 942 healthy adults found insufficient evidence that probiotics improve blood lipid levels [80].
Specific strains with cholesterol-lowering evidence:
- Lactobacillus reuteri NCIMB 30242 in yogurt, twice daily for 6 weeks: lowered LDL and total cholesterol more than placebo in 114 adults with high cholesterol [81]
- L. acidophilus La5 + B. lactis Bb12 in yogurt, 300 g/day for 8 weeks: lowered total and LDL cholesterol more than ordinary yogurt in 72 people with fatty liver disease [82]
- L. curvatus HY7601 + L. plantarum KY1032, 5 billion CFU each daily for 12 weeks: triglycerides fell 20% in 92 adults with high triglycerides [83]
Obesity and Weight Management
The gut microbiota plays an important role in nutrient and energy extraction from food. Research in mice suggests the gut microbiome affects energy expenditure and storage, though whether these effects translate to humans is uncertain [85].
Clinical evidence has been mixed:
- Lactobacillus gasseri SBT2055 (LG2055): An RCT of 210 adults with high visceral fat found that 12 weeks of fermented milk containing 10^7 or 10^6 CFU/g produced significant reductions in visceral fat area (8.5% and 8.2% respectively), BMI, waist and hip circumference, and body fat mass versus control [86].
- Lactobacillus rhamnosus CGMCC1.3724: An RCT enrolled 125 adults with obesity [138]. Two capsules a day, each with 1.6 x 10^8 CFU plus oligofructose and inulin, for 24 weeks, combined with energy restriction for the first 12 weeks, made no significant difference to weight loss overall, but women taking this probiotic-plus-prebiotic formulation lost significantly more weight than women on placebo [88].
- Bifidobacterium breve B-3: About 50 billion CFU daily as a capsule for 12 weeks lowered fat mass compared with placebo in adults with a tendency to obesity [89].
Systematic review findings:
- A 2017 systematic review of 14 trials (n=1,067 individuals with overweight or obesity) found that probiotics (mostly Lactobacillus) significantly decreased body weight and/or body fat in 9 trials, had no effect in 3, and increased body weight in 2 [90].
- A meta-analysis of 15 RCTs (n=957) found that probiotics reduced body weight by 0.6 kg, BMI by 0.27 kg/m^2, and fat percentage by 0.6% versus placebo — effects that were small and of questionable clinical significance [91].
- A more recent meta-analysis of 19 trials (n=1,412) found probiotics/synbiotics reduced waist circumference slightly (by 0.82 cm) but had no effect on body weight or BMI [92].
- Another meta-analysis of 14 adult trials, 5 child trials, and 12 infant trials found probiotics promoted a mean loss of 0.54 kg in adults, a gain of 0.20 kg in children, and no significant change in infants [93].
Synthesis: Effects of probiotics on body weight are small and depend on the strain, dose, duration, and patient characteristics. Current evidence does not support probiotics as a meaningful weight loss intervention, though specific strains may produce modest reductions in body fat when combined with dietary changes.
Upper Respiratory Tract Infections (Colds and Flu)
Adults: In 272 healthy adults, taking 10^9 CFU of L. plantarum HEAL 9 (DSM 15312) plus L. paracasei 8700:2 (DSM 13434) every day for 12 weeks cut the share who caught at least one cold from 67% to 55% and shortened the days with symptoms [94].
Children: In 326 children 3 to 5 years old, L. acidophilus NCFM alone or with B. animalis subsp. lactis Bi-07, taken twice daily for 6 months over winter, reduced fever, cough and runny nose, with larger effects from the combination [96]. In children aged 3 to 12 whose household member had fallen ill, 5 billion CFU daily of L. acidophilus DDS-1 plus B. lactis UABLA-12 with 50 mg of fructooligosaccharide did not prevent respiratory infections but shortened them and made them milder [97].
Mental Health: Anxiety and Depression
Anxiety: In healthy volunteers, L. helveticus R0052 plus B. longum R0175 taken daily for 30 days reduced psychological distress scores more than placebo [99].
Depression: In 20 healthy adults given the probiotic and 20 given placebo, 4 weeks of a multispecies product (B. bifidum W23, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24 and Lactococcus lactis W19 and W58) reduced reactivity to sad mood, mainly rumination and aggressive thoughts [100].
The evidence for probiotic effects on mental health remains preliminary and largely limited to individual small studies. While the gut-brain axis provides a plausible mechanism, well-designed large-scale RCTs are needed to confirm these findings.
Migraine
Evidence on probiotics for migraine is too limited to support any strain.
Diverticular Disease
In 210 patients whose diverticular disease caused symptoms without complications, L. casei subsp. DG at 24 billion a day, taken 10 days/month for 12 months, cut symptom recurrence to 14.5% against 46.0% on placebo, and no one relapsed when it was combined with mesalazine [103]. In 84 people with acute uncomplicated diverticulitis, adding a three-strain mix (B. lactis LA 304, L. salivarius LA 302 and L. acidophilus LA 201) to antibiotics eased pain faster and shortened hospital stays [104].
Vaginal Health
In 64 healthy women, daily capsules containing L. rhamnosus GR-1 plus L. fermentum RC-14 for 60 days reduced the growth of potentially harmful bacteria and yeast in the vagina, and restored normal flora in 37% of women with bacterial vaginosis flora against 13% on placebo [105].
Periodontitis
In a trial of chronic periodontitis (15 people on the probiotic, 15 on placebo), L. reuteri lozenges taken twice daily for 12 weeks after scaling and root planing gave more pocket-depth reduction in moderate and deep periodontal pockets than placebo [106].
Mastitis
In 352 breastfeeding women with infectious mastitis, L. fermentum CECT5716 and L. salivarius CECT5713 (each tested in its own group) at 10^9 CFU (9 log10 CFU) daily for 3 weeks brought more improvement and fewer recurrences than antibiotics [107].
Allergy
In 425 adults whose grass pollen allergy was already being treated with loratadine, L. paracasei LP-33 for 5 weeks improved rhinitis quality of life and eye symptoms but not nasal symptoms [108].
Necrotizing Enterocolitis (NEC) in Preterm Infants
NEC is a life-threatening gastrointestinal illness primarily affecting preterm infants with very low birth weight (less than 1,500 g) [109]. Certain probiotics can block inflammatory signaling pathways in intestinal cells and strengthen the gut barrier [109, 110, 111, 112].
Evidence: A 2020 AGA technical review of 63 trials (n=15,712 preterm infants) found that specific combinations of Lactobacillus and Bifidobacterium strains reduced the risk of all-cause mortality, severe NEC, and time to full enteral feeds [68]. A 2023 systematic review of 90 trials confirmed that multi-strain probiotics reduce mortality, severe NEC, feeding intolerance, and hospitalization duration [113]. However, a Cochrane Review stated the evidence is inconclusive for very preterm infants (born before 32 weeks) and very low birth weight infants (less than 1,500 g) [114].
Guidelines: ESPGHAN (2023) recommends LGG (1-6 x 10^9 CFU) or the combination of B. infantis, B. lactis, and S. thermophilus (3.0-3.5 x 10^8 CFU per strain) for NEC prevention in preterm infants, though grade of recommendation is weak and certainty of evidence is low [51]. AGA recommends specific Lactobacillus-Bifidobacterium combinations for preterm, low-birth-weight infants [68]. The WHO (2023) states probiotics may be considered for human-milk-fed preterm infants born before 32 weeks gestation [115].
FDA safety concern: In 2023, the FDA warned that administering probiotics to preterm infants may cause infection or invasive, potentially fatal disease [116, 138].
PPI-Induced Bloating
In 100 people taking pantoprazole long term, L. paracasei F19 twice daily, three days a week for six months, reduced bloating and flatulence compared with placebo [117].
Chemotherapy-Induced Diarrhea
LGG at 1-2 x 10^10 CFU daily reduced grade 3 or 4 diarrhea (22 vs 37%) in 150 people having 5-FU chemotherapy for colorectal cancer [118].
4. Recommended Dosing
Probiotic dosing is inherently strain-specific. There is no universal "optimal dose" — the effective dose depends entirely on the specific organism and the target condition. The following table summarizes evidence-based dosing for the most well-studied applications:
Dosing Summary Table
| Condition | Strain(s) | Daily dose used in trials | Source |
|---|---|---|---|
| AAD prevention (children) | LGG | 1-2 x 10^10 CFU | [138] |
| AAD prevention (adult inpatients) | L. acidophilus CL1285 + L. casei LBC80R | 50 or 100 billion CFU | [47] |
| AAD prevention (children with risk factors) | LGG or S. boulardii | 5 x 10^9 CFU or more | [138] |
| IBS (women) | B. infantis 35624 | 1 x 10^8 CFU (capsule) | [34] |
| Childhood functional abdominal pain | L. reuteri DSM 17938 | 2 x 10^8 CFU | [40] |
| Eczema prevention | L. rhamnosus HN001 | 6 billion CFU (mother, then infant) | [60] |
| Colds (adults) | L. plantarum HEAL 9 + L. paracasei 8700:2 | 10^9 CFU | [94] |
| NEC prevention (preterm infants, in hospital) | LGG, or B. infantis + B. lactis + S. thermophilus | 1-6 x 10^9 CFU (LGG) or 3.0-3.5 x 10^8 CFU per strain | [138] |
General Dosing Principles
- Timing: Bacterial probiotics may survive best when taken with food, ideally a meal with some fat, or shortly before it [18]. For AAD prevention, start the probiotic within 2 days of the first antibiotic dose [138].
- Duration: For a specific condition, follow the duration used in trials of that strain.
Product Selection Guidance
The World Gastroenterology Organisation (WGO) recommends that clinicians only advise patients to use probiotic strains, doses, and durations that have been shown beneficial in human studies [2]. When selecting a product:
- Match the strain to the condition. A probiotic proven for AAD prevention may have no effect on IBS.
- Look for specific strain designations (e.g., L. rhamnosus GG, not just "Lactobacillus rhamnosus"). Products using unspecified strains may not provide the same benefits as those used in research.
- Check CFU at expiration, not at manufacture. Products should guarantee CFU counts through the "Best By" date.
- Note storage requirements. Some products require refrigeration; others are shelf-stable.
- Be cautious of multi-strain products without evidence. While some tested multi-strain combinations are effective, many commercial products contain untested combinations. A 2024 sequencing study of 50 widely available US probiotic supplements found labeling errors in about one third of them [119].
5. Safety and Side Effects
General Safety Profile
Many probiotic strains derive from species with a long history of safe use in foods or from microorganisms that naturally colonize healthy GI tracts. Common probiotics — Bifidobacterium and members of the Lactobacillaceae family — are unlikely to cause harm in healthy people [2]. Side effects are usually minor [138], and in randomized trials short-term use did not raise the overall rate of adverse events compared with control groups [121].
Serious Adverse Events
In rare cases, probiotics have led to bacteremia, fungemia or other serious infections, nearly always in people who were severely ill or immunocompromised, fed through a tube, or had a central venous catheter [120, 121, 124]:
- Lactobacillus bacteremia: A retrospective analysis of 22,174 ICU patients found that those receiving LGG (typically through a feeding tube) had a markedly higher risk of developing Lactobacillus bacteremia — 6 confirmed cases among 522 LGG recipients versus 2 among 21,652 non-recipients [122]. Population monitoring in Finland after LGG was introduced to dairy products in 1990 showed no increase in Lactobacillus bacteremia rates through 2000 in the general population [123].
- Saccharomyces fungemia: At least 60 reports since 1966 of fungemia associated with S. cerevisiae/S. boulardii probiotic use. In many cases, patients were in ICUs, receiving enteral/parenteral nutrition, had central venous catheters, or were on broad-spectrum antimicrobials [124]. Opening capsules or sachets near patients with central lines may carry a risk, so hospital staff may need extra care when handling them.
- Bacillus subtilis: Has caused bacteremia with a sepsis-like illness in hospital patients, most of whom had cancer, some after taking oral B. subtilis spores [125, 126].
- Contamination risk in premature infants: In 2014, a preterm infant born at 29 weeks who had been given a contaminated probiotic powder from the first day of life died of gastrointestinal mucormycosis, a rare mold infection [139].
- Fatal endocarditis: A young patient with complicated liver cirrhosis and earlier C. difficile colitis died of L. rhamnosus endocarditis that the authors thought may have come from a probiotic containing lactobacilli [129].
If you take a probiotic while seriously ill or immunocompromised and develop a fever with shivering, confusion or a racing heart, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.
Abdominal Surgery
Probiotics taken around major abdominal surgery may raise the chance of hospital readmission. In a trial of 135 patients having major gastrointestinal operations, those given VSL#3 (a dose just before the operation, then twice a day, up to 15 doses in total) were more often readmitted within 30 days (16.4% vs 4.4%), often for dehydration from diet intolerance or diarrhea. The probiotic did not change 30-day infection rates [130].
Allergic Reactions
- Milk allergies: Some bacterial probiotics are grown on milk-based media, so a product may contain traces of milk protein even when it is labeled dairy-free. People with a milk allergy can check with the manufacturer.
- Yeast allergies: People with a yeast allergy may want to avoid S. boulardii and S. cerevisiae products.
- Prebiotic allergies: Anaphylaxis from inulin, a prebiotic found in some vegetables and processed foods, has been reported [133]. With trouble breathing or swelling of the face or throat, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK).
Eosinophilic Syndrome
Two cases of a severe eosinophilic syndrome, with very high eosinophil counts, nerve damage (mononeuritis multiplex) and inflamed blood vessels, were reported in 2012 soon after the people started nonprescription probiotics. Both improved quickly with immunosuppressive treatment but were left with permanent nerve deficits [134].
Special Populations
- Immunocompromised individuals: The WGO advises restricting probiotic use to strains and indications with proven efficacy [2].
- Preterm infants: FDA has raised safety concerns; use only under medical supervision with quality-assured products [116, 138].
- Pregnant and breastfeeding women: Certain strains have been used safely during pregnancy and lactation in multiple RCTs (e.g., LGG, L. rhamnosus HN001), but general safety data is limited. If you are pregnant or breastfeeding, ask your doctor before drinking kombucha.
6. Drug Interactions
Known Interactions
- Antibiotics: Antibiotics can kill bacterial probiotics. Ask your pharmacist how to time the two.
- Prescription medicines: If you take prescription medicines, check with your doctor or pharmacist before starting.
- Blood sugar-lowering medications: In a study in diabetic rats, kombucha lowered blood sugar [137]. Whether this happens in people is unknown, but people who take blood sugar-lowering medicines may want to bear it in mind if they drink kombucha.
- Immunosuppressants: Individuals on immunosuppressive therapy should consult their physician before taking probiotics, as the risk of opportunistic infection from probiotic organisms is elevated in this population [2].
Vitamins and Minerals
No interactions between probiotics and vitamins or minerals are established.
7. Dietary Sources
Fermented Foods Containing Live Cultures
| Food | Key Organisms | Probiotic Status | Notes |
|---|---|---|---|
| Yogurt (with "live and active cultures") | L. bulgaricus, S. thermophilus, sometimes Bifidobacterium and other added strains | Potentially probiotic (depends on strains) | Check the label for "live and active cultures". Avoid products treated after culturing [20]. |
| Kefir | Diverse lactic acid bacteria and yeasts | Potentially probiotic | Contains wider microbial diversity than yogurt |
| Kimchi | Various lactic acid bacteria | Contains live cultures, not proven probiotic | Fermented cabbage dish; microbial content varies [21] |
| Sauerkraut (unpasteurized) | Various lactic acid bacteria | Contains live cultures, not proven probiotic | Must be unpasteurized to contain live organisms |
| Miso | Various bacteria and fungi | Contains live cultures, not proven probiotic | Fermented soybean paste [21] |
| Kombucha | Various bacteria and yeasts | Contains live cultures, not proven probiotic | See safety considerations in Section 2 |
| Some cheeses | Various bacteria | Contains live cultures, not proven probiotic | Not all cheeses contain live cultures |
Practical Notes
- Fermented foods that are heated after fermentation (sourdough bread, pasteurized sauerkraut, most commercial pickles) do not contain live organisms [20].
- A food-first approach that includes regular consumption of fermented foods is reasonable for general gut health, but for specific therapeutic effects, targeted supplementation with strains that have clinical evidence is more appropriate.
From the MicroVitamin range
MicroVitamin+ Powder is not a probiotic, but each daily scoop includes 5 g of acacia fiber, a soluble fiber with prebiotic effects. Prebiotic fiber provides food for the beneficial microbes already in your gut, so it can complement fermented foods or a probiotic. See MicroVitamin+ Powder
8. References
[1] Hill C, Guarner F, Reid G, et al. "The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic." Nat Rev Gastroenterol Hepatol. 2014;11:506-14. https://pubmed.ncbi.nlm.nih.gov/24912386/
[2] Guarner F, Sanders ME, Szajewska H, Cohen H, et al. "World Gastroenterology Organisation Global Guidelines: Probiotics and prebiotics." World Gastroenterology Organisation, 2023:1-52.
[3] Gibson GR, Hutkins R, Sanders ME, et al. "Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics." Nat Rev Gastroenterol Hepatol. 2017;14:491-502. https://pubmed.ncbi.nlm.nih.gov/28611480/
[4] Salminen S, Collado MC, Endo A, et al. "The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics." Nat Rev Gastroenterol Hepatol. 2021;18:649-67. https://pubmed.ncbi.nlm.nih.gov/33948025/
[5] Zmora N, Zilberman-Schapira G, Suez J, et al. "Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features." Cell. 2018;174:1388-405.e21. https://pubmed.ncbi.nlm.nih.gov/30193112/
[6] Sanders ME. "Probiotics in 2015: their scope and use." J Clin Gastroenterol. 2015;49 Suppl 1:S2-6. https://pubmed.ncbi.nlm.nih.gov/26447958/
[7] Sanders ME. "Clinical use of probiotics: what physicians need to know." Am Fam Physician. 2008;78:1026. https://pubmed.ncbi.nlm.nih.gov/19007049/
[8] Zheng J, Wittouck S, Salvetti E, et al. "A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae." Int J Syst Evol Microbiol. 2020;70:2782-858. https://pubmed.ncbi.nlm.nih.gov/32293557/
[9] McFarland LV. "Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity." Dig Dis Sci. 2021. https://doi.org/10.1007/s10620-020-06244-z https://pubmed.ncbi.nlm.nih.gov/32274669/
[10] Office of Dietary Supplements, NIH. "Dietary Supplement Label Database." 2025.
[13] Food and Drug Administration. "Policy regarding quantitative labeling of dietary supplements containing live microbials: Guidance for industry." 2018.
[14] International Probiotics Association. "Best practices document for probiotics." 2017.
[15] International Scientific Association for Probiotics and Prebiotics. "Deciphering a probiotic label." 2022.
[18] Tompkins TA, et al. "The impact of meals on a probiotic during transit through a model of the human upper gastrointestinal tract." Benef Microbes. 2011. https://pubmed.ncbi.nlm.nih.gov/22146689/
[20] Marco ML, Sanders ME, Ganzle M, et al. "The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods." Nat Rev Gastroenterol Hepatol. 2021;18:196-208. https://pubmed.ncbi.nlm.nih.gov/33398112/
[21] Hogan DE, Ivanina EA, Robbins DH. "Probiotics: a review for clinical use." Gastroenterology & Endoscopy News. 2018:1-7.
[23] Holbourn A, et al. "Kombucha: is a cup of tea good for you?" BMJ Case Rep. 2017. https://pubmed.ncbi.nlm.nih.gov/29197835/
[24] Lind L, et al. "Erosive potential of ice tea beverages and kombuchas." Acta Odontol Scand. 2023. https://pubmed.ncbi.nlm.nih.gov/37192014/
[27] Staudacher HM, Whelan K. "Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet." Proc Nutr Soc. 2016;75:306-18. https://pubmed.ncbi.nlm.nih.gov/26908093/
[28] Zhuang X, Xiong L, Li L, et al. "Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis." J Gastroenterol Hepatol. 2017;32:28-38. https://pubmed.ncbi.nlm.nih.gov/27300149/
[29] Ford AC, Quigley EM, Lacy BE, et al. "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis." Am J Gastroenterol. 2014;109:1547-61. https://pubmed.ncbi.nlm.nih.gov/25070051/
[30] Didari T, Mozaffari S, Nikfar S, Abdollahi M. "Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis." World J Gastroenterol. 2015;21:3072-84. https://pubmed.ncbi.nlm.nih.gov/25780308/
[31] Lorenzo-Zuniga V, Llop E, Suarez C, et al. "I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life." World J Gastroenterol. 2014;20:8709-16. https://pubmed.ncbi.nlm.nih.gov/25024629/
[32] Williams EA, Stimpson J, Wang D, et al. "Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study." Aliment Pharmacol Ther. 2009;29:97-103. https://pubmed.ncbi.nlm.nih.gov/18785988/
[33] Ortiz-Lucas M, Tobias A, Saz P, Sebastian JJ. "Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis." Rev Esp Enferm Dig. 2013;105:19-36. https://pubmed.ncbi.nlm.nih.gov/23548007/
[34] Whorwell PJ, et al. "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome." Am J Gastroenterol. 2006. https://pubmed.ncbi.nlm.nih.gov/16863564/
[35] Sisson G, et al. "Randomised clinical trial: a liquid multi-strain probiotic vs placebo in the irritable bowel syndrome." Aliment Pharmacol Ther. 2014. https://pubmed.ncbi.nlm.nih.gov/24815298/
[36] Kim HJ, et al. "A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome." Aliment Pharmacol Ther. 2003. https://pubmed.ncbi.nlm.nih.gov/12656692/
[38] Majeed M, et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome." Nutr J. 2016. https://pubmed.ncbi.nlm.nih.gov/26922379/
[39] Francavilla R, et al. "A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain." Pediatrics. 2010. https://pubmed.ncbi.nlm.nih.gov/21078735/
[40] Romano C, et al. "Lactobacillus reuteri in children with functional abdominal pain (FAP)." J Paediatr Child Health. 2014. https://pubmed.ncbi.nlm.nih.gov/20626584/
[41] Silverman MA, Konnikova L, Gerber JS. "Impact of antibiotics on necrotizing enterocolitis and antibiotic-associated diarrhea." Gastroenterol Clin North Am. 2017;46:61-76. https://pubmed.ncbi.nlm.nih.gov/28164853/
[42] Blaabjerg S, Artzi DM, Aabenhus R. "Probiotics for the prevention of antibiotic-associated diarrhea in outpatients — a systematic review and meta-analysis." Antibiotics (Basel). 2017;6. https://pubmed.ncbi.nlm.nih.gov/29023420/
[44] Jafarnejad S, Shab-Bidar S, Speakman JR, et al. "Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (>65 years): a meta-analysis." Nutr Clin Pract. 2016;31:502-13. https://pubmed.ncbi.nlm.nih.gov/27130655/
[45] Szajewska H, Kolodziej M. "Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults." Aliment Pharmacol Ther. 2015;42:1149-57. https://pubmed.ncbi.nlm.nih.gov/26365389/
[46] Szajewska H, Kolodziej M. "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea." Aliment Pharmacol Ther. 2015;42:793-801. https://pubmed.ncbi.nlm.nih.gov/26216624/
[47] Gao XW, et al. "Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea." Am J Gastroenterol. 2010. https://pubmed.ncbi.nlm.nih.gov/20145608/
[48] Ouwehand AC, et al. "Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study." Vaccine. 2014. https://pubmed.ncbi.nlm.nih.gov/24291194/
[49] Kabbani TA, et al. "Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate on the gut microbiota." Gut Microbes. 2017. https://pubmed.ncbi.nlm.nih.gov/27973989/
[50] Evans M, et al. "Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults." Br J Nutr. 2016. https://pubmed.ncbi.nlm.nih.gov/27169634/
[51] Szajewska H, Berni Canani R, Domellof M, et al. "Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications." J Pediatr Gastroenterol Nutr. 2023;76:232-47. https://pubmed.ncbi.nlm.nih.gov/36219218/
[52] Suez J, et al. "Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT." Cell. 2018. https://pubmed.ncbi.nlm.nih.gov/30193113/
[53] Avena-Woods C. "Overview of atopic dermatitis." Am J Manag Care. 2017;23:S115-S23. https://pubmed.ncbi.nlm.nih.gov/28978208/
[54] Li L, Han Z, Niu X, et al. "Probiotic Supplementation for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-analysis." Am J Clin Dermatol. 2019;20:367-77. https://pubmed.ncbi.nlm.nih.gov/30465329/
[55] Szajewska H, Horvath A. "Lactobacillus rhamnosus GG in the primary prevention of eczema in children: a systematic review and meta-analysis." Nutrients. 2018;10. https://pubmed.ncbi.nlm.nih.gov/30231505/
[56] Huang R, Ning H, Shen M, et al. "Probiotics for the treatment of atopic dermatitis in children: a systematic review and meta-analysis of randomized controlled trials." Front Cell Infect Microbiol. 2017;7:392. https://pubmed.ncbi.nlm.nih.gov/28932705/
[57] Zhao M, Shen C, Ma L. "Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis." Int J Dermatol. 2018;57:635-41. https://pubmed.ncbi.nlm.nih.gov/29417549/
[58] Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et al. "Probiotics for treating eczema." Cochrane Database Syst Rev. 2018;11:CD006135. https://pubmed.ncbi.nlm.nih.gov/30480774/
[60] Wickens K, et al. "Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years." Pediatr Allergy Immunol. 2018. https://pubmed.ncbi.nlm.nih.gov/30430649/
[61] Guarino A, Ashkenazi S, Gendrel D, et al. "European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children." J Pediatr Gastroenterol Nutr. 2014;59:132-52. https://pubmed.ncbi.nlm.nih.gov/24739189/
[62] Collinson S, Deans A, Padua-Zamora A, et al. "Probiotics for treating acute infectious diarrhoea." Cochrane Database Syst Rev. 2020;12:CD003048. https://pubmed.ncbi.nlm.nih.gov/33295643/
[63] Caffarelli C, Cardinale F, Povesi-Dascola C, et al. "Use of probiotics in pediatric infectious diseases." Expert Rev Anti Infect Ther. 2015;13:1517-35. https://pubmed.ncbi.nlm.nih.gov/26496433/
[64] Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. "Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children — updated analysis of randomised controlled trials." Aliment Pharmacol Ther. 2013;38:467-76. https://pubmed.ncbi.nlm.nih.gov/23841880/
[65] Feizizadeh S, Salehi-Abargouei A, Akbari V. "Efficacy and safety of Saccharomyces boulardii for acute diarrhea." Pediatrics. 2014;134:e176-91. https://pubmed.ncbi.nlm.nih.gov/24958586/
[66] Freedman SB, Williamson-Urquhart S, Farion KJ, et al. "Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis." N Engl J Med. 2018;379:2015-26. https://pubmed.ncbi.nlm.nih.gov/30462939/
[67] Schnadower D, Tarr PI, Casper TC, et al. "Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children." N Engl J Med. 2018;379:2002-14. https://pubmed.ncbi.nlm.nih.gov/30462938/
[68] Su GL, Ko CW, Bercik P, et al. "AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders." Gastroenterology. 2020;159:697-705. https://pubmed.ncbi.nlm.nih.gov/32531291/
[69] Hilton E, et al. "Efficacy of Lactobacillus GG as a diarrheal preventive in travelers." J Travel Med. 1997. https://pubmed.ncbi.nlm.nih.gov/9815476/
[70] Kollaritsch H, et al. "Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study" (in German). Fortschr Med. 1993. https://pubmed.ncbi.nlm.nih.gov/8486328/
[71] Kaur L, Gordon M, Baines PA, et al. "Probiotics for induction of remission in ulcerative colitis." Cochrane Database Syst Rev. 2020;3:CD005573. https://pubmed.ncbi.nlm.nih.gov/32128795/
[72] Iheozor-Ejiofor Z, Kaur L, Gordon M, et al. "Probiotics for maintenance of remission in ulcerative colitis." Cochrane Database Syst Rev. 2020;3:CD007443. https://pubmed.ncbi.nlm.nih.gov/32128794/
[73] Lamb CA, Kennedy NA, Raine T, et al. "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults." Gut. 2019;68:s1-s106. https://pubmed.ncbi.nlm.nih.gov/31562236/
[74] Tsai CC, Lin PP, Hsieh YM, et al. "Cholesterol-lowering potentials of lactic acid bacteria based on bile-salt hydrolase activity." ScientificWorldJournal. 2014;2014:690752. https://pubmed.ncbi.nlm.nih.gov/25538960/
[75] Kumar R, Grover S, Batish VK. "Bile salt hydrolase activity screening of lactobacilli." Probiotics Antimicrob Proteins. 2012;4:162-72. https://pubmed.ncbi.nlm.nih.gov/26782042/
[76] Ishimwe N, Daliri EB, Lee BH, et al. "The perspective on cholesterol-lowering mechanisms of probiotics." Mol Nutr Food Res. 2015;59:94-105. https://pubmed.ncbi.nlm.nih.gov/25403164/
[77] Cho YA, Kim J. "Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials." Medicine (Baltimore). 2015;94:e1714. https://pubmed.ncbi.nlm.nih.gov/26512560/
[78] Shimizu M, Hashiguchi M, Shiga T, et al. "Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals." PLoS One. 2015;10:e0139795. https://pubmed.ncbi.nlm.nih.gov/26473340/
[79] Sun J, Buys N. "Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials." Ann Med. 2015;47:430-40. https://pubmed.ncbi.nlm.nih.gov/26340330/
[80] Khalesi S, Bellissimo N, Vandelanotte C, et al. "A review of probiotic supplementation in healthy adults: helpful or hype?" Eur J Clin Nutr. 2019;73:24-37. https://pubmed.ncbi.nlm.nih.gov/29581563/
[81] Jones ML, et al. "Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242." Eur J Clin Nutr. 2012. https://pubmed.ncbi.nlm.nih.gov/22067612/
[82] Nabavi S, et al. "Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease." J Dairy Sci. 2014. https://pubmed.ncbi.nlm.nih.gov/25306266/
[83] Ahn HY, et al. "The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects." Nutr Metab Cardiovasc Dis. 2015. https://pubmed.ncbi.nlm.nih.gov/26044516/
[85] Davis CD. "The gut microbiome and its role in obesity." Nutr Today. 2016;51:167-74. https://pubmed.ncbi.nlm.nih.gov/27795585/
[86] Kadooka Y, Sato M, Ogawa A, et al. "Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial." Br J Nutr. 2013;110:1696-703. https://pubmed.ncbi.nlm.nih.gov/23614897/
[88] Sanchez M, Darimont C, Drapeau V, et al. "Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women." Br J Nutr. 2014;111:1507-19. https://pubmed.ncbi.nlm.nih.gov/24299712/
[89] Minami J, et al. "Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies." J Nutr Sci. 2015. https://pubmed.ncbi.nlm.nih.gov/26090097/
[90] Crovesy L, Ostrowski M, Ferreira D, et al. "Effect of Lactobacillus on body weight and body fat in overweight subjects: a systematic review of randomized controlled clinical trials." Int J Obes (Lond). 2017;41:1607-14. https://pubmed.ncbi.nlm.nih.gov/28792488/
[91] Borgeraas H, Johnson LK, Skattebu J, et al. "Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials." Obes Rev. 2018;19:219-32. https://pubmed.ncbi.nlm.nih.gov/29047207/
[92] Suzumura EA, Bersch-Ferreira AC, Torreglosa CR, et al. "Effects of oral supplementation with probiotics or synbiotics in overweight and obese adults: a systematic review and meta-analyses of randomized trials." Nutr Rev. 2019;77:430-50. https://pubmed.ncbi.nlm.nih.gov/30924853/
[93] Dror T, Dickstein Y, Dubourg G, Paul M. "Microbiota manipulation for weight change." Microb Pathog. 2017;106:146-61. https://pubmed.ncbi.nlm.nih.gov/26792677/
[94] Berggren A, et al. "Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections." Eur J Nutr. 2011. https://pubmed.ncbi.nlm.nih.gov/20803023/
[96] Leyer GJ, et al. "Probiotic effects on cold and influenza-like symptom incidence and duration in children." Pediatrics. 2009. https://pubmed.ncbi.nlm.nih.gov/19651563/
[97] Gerasimov SV, et al. "Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children." Eur J Clin Nutr. 2015. https://pubmed.ncbi.nlm.nih.gov/26463725/
[99] Messaoudi M, et al. "Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects." Br J Nutr. 2011. https://pubmed.ncbi.nlm.nih.gov/20974015/
[100] Steenbergen L, et al. "A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood." Brain Behav Immun. 2015. https://pubmed.ncbi.nlm.nih.gov/25862297/
[103] Tursi A, et al. "Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease." Aliment Pharmacol Ther. 2013. https://pubmed.ncbi.nlm.nih.gov/23957734/
[104] Petruzziello C, et al. "The efficacy of a mix of three probiotic strains in reducing abdominal pain and inflammatory biomarkers in acute uncomplicated diverticulitis." Int J Colorectal Dis. 2019. https://pubmed.ncbi.nlm.nih.gov/31696504/
[105] Reid G, et al. "Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women." FEMS Immunol Med Microbiol. 2003. https://pubmed.ncbi.nlm.nih.gov/12628548/
[106] Teughels W, et al. "Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis." J Clin Periodontol. 2013. https://pubmed.ncbi.nlm.nih.gov/24164569/
[107] Arroyo R, et al. "Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk." Clin Infect Dis. 2010. https://pubmed.ncbi.nlm.nih.gov/20455694/
[108] Costa DJ, et al. "Efficacy of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis." Eur J Clin Nutr. 2014. https://pubmed.ncbi.nlm.nih.gov/24569538/
[109] Working Group of the National Advisory Council of Child Health and Human Development. "Necrotizing Enterocolitis (NEC) in Preterm Infants, Report to Secretary, Department of Health and Human Services." 2024.
[110] Shaw AG, Sim K, Rose G, et al. "Premature neonatal gut microbial community patterns supporting an epithelial TLR-mediated pathway for necrotizing enterocolitis." BMC Microbiol. 2021;21:225. https://pubmed.ncbi.nlm.nih.gov/34362295/
[111] Lai Z, Gong F. "Protective Effects of Lactobacillus reuteri on Intestinal Barrier Function in a Mouse Model of Neonatal Necrotizing Enterocolitis." Am J Perinatol. 2024;41:e386-e93. https://pubmed.ncbi.nlm.nih.gov/36368653/
[112] Blackwood BP, Yuan CY, Wood DR, et al. "Probiotic Lactobacillus Species Strengthen Intestinal Barrier Function and Tight Junction Integrity in Experimental Necrotizing Enterocolitis." J Probiotics Health. 2017;5. https://pubmed.ncbi.nlm.nih.gov/28638850/
[113] Wang Y, Florez ID, Morgan RL, et al. "Probiotics, Prebiotics, Lactoferrin, and Combination Products for Prevention of Mortality and Morbidity in Preterm Infants: A Systematic Review and Network Meta-Analysis." JAMA Pediatr. 2023;Oct 2:e233849. https://pubmed.ncbi.nlm.nih.gov/37782505/
[114] Sharif S, Meader N, Oddie SJ, et al. "Probiotics to prevent necrotizing enterocolitis in very preterm infants or very low birth weight infants." Cochrane Database Syst Rev. 2023:CD005496. https://pubmed.ncbi.nlm.nih.gov/37493095/
[115] Darmstadt GL, Al Jaifi NH, Arif S, et al. "New World Health Organization recommendations for care of preterm or low birth weight infants: health policy." eClinicalMedicine. 2023;63.
[116] U.S. Food and Drug Administration. "FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants." 2023.
[117] Compare D, et al. "Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial." Dig Liver Dis. 2015. https://pubmed.ncbi.nlm.nih.gov/25660822/
[118] Osterlund P, et al. "Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer." Br J Cancer. 2007. https://pubmed.ncbi.nlm.nih.gov/17895895/
[119] Gundogdu A, et al. "A Shotgun Metagenomics Investigation into Labeling Inaccuracies in Widely Sold Probiotic Supplements in the USA." Mol Nutr Food Res. 2024. https://pubmed.ncbi.nlm.nih.gov/38856022/
[120] Didari T, Solki S, Mozaffari S, et al. "A systematic review of the safety of probiotics." Expert Opin Drug Saf. 2014;13:227-39. https://pubmed.ncbi.nlm.nih.gov/24405164/
[121] Hempel S, Newberry S, Ruelaz A, et al. "Safety of probiotics used to reduce risk and prevent or treat disease." Evid Rep Technol Assess (Full Rep). 2011:1-645. https://pubmed.ncbi.nlm.nih.gov/23126627/
[122] Yellin I, Flett KB, Merakou C, et al. "Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients." Nat Med. 2019;25:1728-32. https://pubmed.ncbi.nlm.nih.gov/31700189/
[123] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis. 2002;35:1155-60. https://pubmed.ncbi.nlm.nih.gov/12410474/
[124] Munoz P, Bouza E, Cuenca-Estrella M, et al. "Saccharomyces cerevisiae fungemia: an emerging infectious disease." Clin Infect Dis. 2005;40:1625-34. https://pubmed.ncbi.nlm.nih.gov/15889360/
[125] Richard V, et al. "Nosocomial bacteremia caused by Bacillus species." Eur J Clin Microbiol Infect Dis. 1988. https://pubmed.ncbi.nlm.nih.gov/3145864/
[126] Oggioni MR, et al. "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol. 1998. https://pubmed.ncbi.nlm.nih.gov/9431982/
[129] Naqvi SSB, et al. "Probiotic related Lactobacillus rhamnosus endocarditis in a patient with liver cirrhosis." IDCases. 2018. https://pubmed.ncbi.nlm.nih.gov/30155406/
[130] Franko J, et al. "Randomized Trial of Perioperative Probiotics Among Patients Undergoing Major Abdominal Operation." J Am Coll Surg. 2019. https://pubmed.ncbi.nlm.nih.gov/31562911/
[133] Gay-Crosier F, et al. "Anaphylaxis from inulin in vegetables and processed food." N Engl J Med. 2000. https://pubmed.ncbi.nlm.nih.gov/10798950/
[134] Mendoza FA, et al. "Severe eosinophilic syndrome associated with the use of probiotic supplements: a new entity?" Case Rep Rheumatol. 2012. https://pubmed.ncbi.nlm.nih.gov/23259129/
[137] Aloulou A, et al. "Hypoglycemic and antilipidemic properties of kombucha tea in alloxan-induced diabetic rats." BMC Complement Altern Med. 2012. https://pubmed.ncbi.nlm.nih.gov/22591682/
[138] National Institutes of Health, Office of Dietary Supplements. "Probiotics: Fact Sheet for Health Professionals." https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
[139] Vallabhaneni S, et al. "Notes from the field: Fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement, Connecticut, 2014." MMWR Morb Mortal Wkly Rep. 2015. https://pubmed.ncbi.nlm.nih.gov/25695322/



